Lucid Diagnostics Begins Medicare Reimbursements and Announces Q3 Results
LUCD Lucid Diagnostics Inc
$0.42 +9.15%
View chart & analysis → - 1Lucid Diagnostics Inc. announced that Medicare reimbursements for esophageal DNA testing have begun to arrive consistently.
- 2The company sold 2,870 tests during the third quarter, recording a billable value of approximately $7.9 million, though recognized revenue was $1.2 million.
- 3In October, the number of tests performed on all patients reached a monthly high of over 1,800.
So what's the key point?
Lucid Diagnostics has started receiving health insurance reimbursements for esophageal genetic testing. While test sales in the third quarter were approximately $7.9 million, the actual recognized revenue was $1.2 million.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.